FOLH1 and prostate carcinoma: Dassie et al. reported significant inhibition of PSMA-positive tumors when treated with a conjugating RNA aptamer targeting prostate-specific membrane antigens (PSMA), specifically expressed in prostate cancer cells with siRNA targeting PLK1 mRNA [162].